CS1/CS2 (FTO inhibitor) treatment decreased the expression of LILRB4 in AML cells and substantially increased the sensitivity of AML cells to the cytotoxicity of activated T cells (81). The gene discussed is FTO; the disease is acute myeloid leukemia.